‘s drug target MR study found that 3-hydroxy-3-methylglutaryl-assisted enzyme A reductase inhibitors (HMGCR) were associated with an elevated risk of PCa (140).Sun X et al., using a drug-targeted MR approach, found that genetically proxied metformin effects were associated with an increased risk of PCa (141).Sun L et al. Here, HMGCR is linked to posterior cortical atrophy.